Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;47(5):1080-1095.
doi: 10.1002/jimd.12773. Epub 2024 Jul 4.

Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis

Antonio Pisani  1 , Kathryn M Wilson  2 , Julie L Batista  3 , Ilkka Kantola  4 , Alberto Ortiz  5   6 , Juan Politei  7 , Laila Al-Shaar  3 , Manish Maski  3 , Ana Crespo  3 , Elvira Ponce  3 , Aleš Linhart  8   9
Affiliations

Clinical outcomes in patients switching from agalsidase beta to migalastat: A Fabry Registry analysis

Antonio Pisani et al. J Inherit Metab Dis. 2024 Sep.

Erratum in

Abstract

Fabry Registry data were analyzed among 83 agalsidase beta-treated patients with Fabry disease who switched to migalastat. Outcomes (estimated glomerular filtration rate [eGFR], urine protein-creatinine ratio [UPCR], plasma globotriaosylceramide [GL-3], plasma globotriaosylsphingosine [lyso-GL-3], interventricular septal wall thickness [IVST], left posterior wall thickness [LPWT], left ventricular mass index [LVMI]) were assessed using linear mixed models to estimate annual change over time in the pre- and postswitch periods. eGFR decreased throughout both periods (preswitch: -0.85 mL/min/1.73 m2/year; postswitch: -1.96 mL/min/1.73 m2/year; both p < 0.0001), with steeper decline postswitch (ppre/post = 0.01) in both classic and late-onset patients. UPCR increased significantly postswitch (ppre/post = 0.003) among classic patients and was stable in both periods among late-onset patients. GL-3 trajectories worsened postswitch across phenotypes (ppre/post = 0.0005 classic, 0.02 late-onset). LPWT was stable preswitch (0.07 mm/year, p = 0.25) and decreased postswitch (-0.51 mm/year, p = 0.0005; ppre/post = 0.0009), primarily among late-onset patients. IVST and LVMI slopes varied significantly by phenotype. Among classic patients, IVST and LVMI were stable and decreasing, respectively preswitch and increasing postswitch (ppre/post = 0.02 IVST, 0.01 LVMI). Among late-onset patients, IVST significantly decreased postswitch (ppre/post = 0.0003); LVMI was stable over time (ppre/post = 0.89). Ultimately, eGFR and GL-3 trajectories worsened postswitch across phenotypes, while UPCR and cardiac measures worsened among classic and stabilized/improved among late-onset patients. These findings indicate variability in long-term outcomes after switching from ERT to migalastat, underscoring the importance of careful monitoring.

Keywords: Fabry disease; agalsidase beta; chaperone; enzyme replacement therapy (ERT); migalastat.

PubMed Disclaimer

References

REFERENCES

    1. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi:10.1186/1750‐1172‐5‐30
    1. Svarstad E, Marti HP. The changing landscape of Fabry disease. Clin J Am Soc Nephrol. 2020;15(4):569‐576. doi:10.2215/cjn.09480819
    1. Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631‐1641. doi:10.1681/asn.2016090964
    1. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416‐427. doi:10.1016/j.ymgme.2018.02.014
    1. Pieroni M, Moon JC, Arbustini E, et al. Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol. 2021;77(7):922‐936. doi:10.1016/j.jacc.2020.12.024

Publication types

MeSH terms

Grants and funding

LinkOut - more resources